Studie KEYNOTE 937

KEYNOTE 937

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation

2. Med 2. Med Ismaninger Str. 22 81675 München Germany

III

Rekrutierung aktiv

Unbekannt / Unbekannt

1

Chemo - Therapieart: adjuvant